The incidences of adverse events in the secukinumab groupings during induction and the entire 52-week treatment period in the FIXTURE study were like the incidence with etanercept. There have been no apparent dose-related differences between your secukinumab groups regarding adverse events, with the exception of gentle and moderate candida infections. Interleukin-17A plays a key role in host protection, specifically in mucocutaneous microbial surveillance.At 2. Almost a year afterwards, computed tomography of the upper body showed a new pulmonary infiltrate . A lung biopsy revealed granulomatous swelling with acid-fast bacilli. Mycobacterium avium was cultured from the biopsy specimen, and human being herpesvirus-6 DNA was detected. Immunologic investigations exposed T-cell and B-cellular lymphopenia, defective in vitro T-cell proliferation, and too little specific antibody responses , which were consistent with mixed immunodeficiency. At age 3.8 years, after reduced-intensity conditioning by using treosulfan, fludarabine, and alemtuzumab, she underwent HLA-matched unrelated-donor HSCT.